

NEW CLINICAL TRIAL OPEN FOR INCLUSION

PROTOCOL TITLE

Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functional imaging

ALIAS

PEACE 8

CTO NUMBER

CTO24061UNI

SPONSOR

Unicancer

KEY INCLUSION AND EXCLUSION CRITERIA


Patients with castration resistant prostate cancer

Detection of 1 to 5 metastatic sites (pelvic lymph nodes included) on new generation PET using either choline, fluciclovine, or PSMA as tracer.

All metastatic sites must be amenable to stereotactic radiation therapy.

Patients are not eligible when previously treated for metastatic prostate cancer with a novel hormonal agent (NHA), a CYP17 inhibitor, ketoconazole, chemotherapy or immunotherapy

DESIGN



PRINCIPAL INVESTIGATOR

Dr. Piet Ost

piet.ost@zas.be

STUDY COORDINATOR(S)

Tine Loeman

tine.loeman@zas.be

Jo Horemans

Jo.Horemans@zas.be

Instructies

- Tekst sjabloon en figuur design vervangen met correcte inhoud.
- Voornaamste in- en exclusie criteria opvragen bij PI
- Ingevulde ppt bewaren als jpeg, tiff of png bestand.
- Figuur invoegen in e-mail via tab “Invoegen” en vervolgens “Afbeeldingen”.